GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Paul LaBarre has joined the leadership team as Vice President, Global Business Development. Mr. LaBarre is a global business executive with over 20 years of global health experience across the innovation value chain including strategy, research, product development, and strategic business development, most notably with UNICEF and PATH. In this role he will be leading business development and commercialization strategies for the PharmaJet organization replacing Melissa Malhame who transitioned to a strategic advisory role for the company.
Chris Cappello, President and CEO, PharmaJet Inc. said, “We are very pleased to add Mr. LaBarre to the PharmaJet leadership team. His extensive experience with UNICEF and PATH will help drive the product development and support for the expansion and use of our Needle-free injection system technology.”
Since 1997 Mr. LaBarre has held key business development roles at prominent healthcare support organizations including UNICEF and PATH, in addition to other health related organizations. Most recently he was Senior Vice President, Access and Innovation for SightLife, the world's leading eye bank and global nonprofit organization dedicated to eliminating corneal blindness by 2040, where he was responsible for building an innovation program to support their mission. Prior to this, at UNICEF and PATH, he drove the development of health innovations for low- and middle-income region markets in the newborn health, maternal health, and health emergency sectors. He also directed a portfolio of global health projects that included diagnostics, vaccine cold-chain, and drug delivery innovations. Mr. LaBarre holds an MBA from Mount Vernon Nazarene University, a Master of Medical Engineering from the University of Washington, and a Bachelor of Science degree in Mechanical Engineering from Northwestern University.
Mr. LaBarre added, “I am delighted to be joining the incredibly talented PharmaJet leadership team and look forward to directing my skills and expertise to expanding the health impact of the PharmaJet technology. PharmaJet is already contributing to improved vaccine solutions eliminating the burden of longstanding infectious diseases such as polio without the inconvenience of needles. I am equally excited about the potential for PharmaJet innovations to address the current COVID pandemic, improve preparations for future pandemics, as well as help advance a technology that provides better treatment solutions for Nucleic Acid-based drugs/vaccines.”
For more information about PharmaJet visit www.pharmajet.com.
About PharmaJet
PharmaJet’s mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market. The PharmaJet Needle-free Systems are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
